These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

123 related items for PubMed ID: 10811509

  • 1. MTHFR gene polymorphism and severe toxicity during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil (CMF).
    Toffoli G, Veronesi A, Boiocchi M, Crivellari D.
    Ann Oncol; 2000 Mar; 11(3):373-4. PubMed ID: 10811509
    [No Abstract] [Full Text] [Related]

  • 2. Influence of chemotherapeutic drug-related gene polymorphisms on toxicity and survival of early breast cancer patients receiving adjuvant chemotherapy.
    Ludovini V, Antognelli C, Rulli A, Foglietta J, Pistola L, Eliana R, Floriani I, Nocentini G, Tofanetti FR, Piattoni S, Minenza E, Talesa VN, Sidoni A, Tonato M, Crinò L, Gori S.
    BMC Cancer; 2017 Jul 26; 17(1):502. PubMed ID: 28747156
    [Abstract] [Full Text] [Related]

  • 3. Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast cancer: a study by the GEICAM group.
    Martin M, Villar A, Sole-Calvo A, Gonzalez R, Massuti B, Lizon J, Camps C, Carrato A, Casado A, Candel MT, Albanell J, Aranda J, Munarriz B, Campbell J, Diaz-Rubio E, GEICAM Group (Spanish Breast Cancer Research Group), Spain.
    Ann Oncol; 2003 Jun 26; 14(6):833-42. PubMed ID: 12796019
    [Abstract] [Full Text] [Related]

  • 4. Comparison of adjuvant chemotherapy with methotrexate and fluorouracil with and without cyclophosphamide in breast cancer patients with one to three positive axillary lymph nodes.
    Shapiro CL, Gelman RS, Hayes DF, Osteen R, Obando A, Canellos GP, Frei E, Henderson IC.
    J Natl Cancer Inst; 1993 May 19; 85(10):812-7. PubMed ID: 8487326
    [Abstract] [Full Text] [Related]

  • 5. Influence of thymidylate synthase and methylenetetrahydrofolate reductase gene polymorphisms on the disease-free survival of breast cancer patients receiving adjuvant 5-fluorouracil/methotrexate-based therapy.
    Paré L, Altés A, Ramón y Cajal T, Del Rio E, Alonso C, Sedano L, Barnadas A, Baiget M.
    Anticancer Drugs; 2007 Aug 19; 18(7):821-5. PubMed ID: 17581305
    [Abstract] [Full Text] [Related]

  • 6. Sequential methotrexate and fluorouracil for the treatment of node-negative breast cancer patients with estrogen receptor-negative tumors: eight-year results from National Surgical Adjuvant Breast and Bowel Project (NSABP) B-13 and first report of findings from NSABP B-19 comparing methotrexate and fluorouracil with conventional cyclophosphamide, methotrexate, and fluorouracil.
    Fisher B, Dignam J, Mamounas EP, Costantino JP, Wickerham DL, Redmond C, Wolmark N, Dimitrov NV, Bowman DM, Glass AG, Atkins JN, Abramson N, Sutherland CM, Aron BS, Margolese RG.
    J Clin Oncol; 1996 Jul 19; 14(7):1982-92. PubMed ID: 8683228
    [Abstract] [Full Text] [Related]

  • 7. Goserelin versus cyclophosphamide, methotrexate, and fluorouracil as adjuvant therapy in premenopausal patients with node-positive breast cancer: The Zoladex Early Breast Cancer Research Association Study.
    Jonat W, Kaufmann M, Sauerbrei W, Blamey R, Cuzick J, Namer M, Fogelman I, de Haes JC, de Matteis A, Stewart A, Eiermann W, Szakolczai I, Palmer M, Schumacher M, Geberth M, Lisboa B, Zoladex Early Breast Cancer Research Association Study.
    J Clin Oncol; 2002 Dec 15; 20(24):4628-35. PubMed ID: 12488406
    [Abstract] [Full Text] [Related]

  • 8. Randomized trial of intensive cyclophosphamide, epirubicin, and fluorouracil chemotherapy compared with cyclophosphamide, methotrexate, and fluorouracil in premenopausal women with node-positive breast cancer. National Cancer Institute of Canada Clinical Trials Group.
    Levine MN, Bramwell VH, Pritchard KI, Norris BD, Shepherd LE, Abu-Zahra H, Findlay B, Warr D, Bowman D, Myles J, Arnold A, Vandenberg T, MacKenzie R, Robert J, Ottaway J, Burnell M, Williams CK, Tu D.
    J Clin Oncol; 1998 Aug 15; 16(8):2651-8. PubMed ID: 9704715
    [Abstract] [Full Text] [Related]

  • 9. Mortality during adjuvant treatment of early breast cancer with cyclophosphamide, methotrexate, and fluorouracil. International Breast Cancer Study Group.
    Colleoni M, Price KN, Castiglione-Gertsch M, Gelber RD, Coates AS, Goldhirsch A.
    Lancet; 1999 Jul 10; 354(9173):130-1. PubMed ID: 10408495
    [Abstract] [Full Text] [Related]

  • 10. Dose-intensive epirubicin-based chemotherapy is superior to an intensive intravenous cyclophosphamide, methotrexate, and fluorouracil regimen in metastatic breast cancer: a randomized multinational study.
    Ackland SP, Anton A, Breitbach GP, Colajori E, Tursi JM, Delfino C, Efremidis A, Ezzat A, Fittipaldo A, Kolaric K, Lopez M, Viaro D, HEPI 013 study group.
    J Clin Oncol; 2001 Feb 15; 19(4):943-53. PubMed ID: 11181656
    [Abstract] [Full Text] [Related]

  • 11. A randomized phase 2 study comparing EC or CMF versus nab-paclitaxel plus capecitabine as adjuvant chemotherapy for nonfrail elderly patients with moderate to high-risk early breast cancer (ICE II-GBG 52).
    von Minckwitz G, Conrad B, Reimer T, Decker T, Eidtmann H, Eiermann W, Hackmann J, Möbus V, Marmé F, Potenberg J, Stickeler E, Simon E, Thomssen C, Huober J, Denkert C, Alfer J, Jackisch C, Nekljudova V, Burchardi N, Loibl S, German Breast Group Investigators.
    Cancer; 2015 Oct 15; 121(20):3639-48. PubMed ID: 26111104
    [Abstract] [Full Text] [Related]

  • 12. Randomized trial comparing cyclophosphamide, methotrexate, and 5-fluorouracil (CMF) with rotational CMF, epirubicin and vincristine as primary chemotherapy in operable breast carcinoma.
    Cocconi G, Di Blasio B, Boni C, Bisagni G, Ceci G, Rondini E, Bella M, Leonardi F, Savoldi L, Camisa R, Bruzzi P.
    Cancer; 2002 Jul 15; 95(2):228-35. PubMed ID: 12124820
    [Abstract] [Full Text] [Related]

  • 13. Oral uracil and tegafur compared with classic cyclophosphamide, methotrexate, fluorouracil as postoperative chemotherapy in patients with node-negative, high-risk breast cancer: National Surgical Adjuvant Study for Breast Cancer 01 Trial.
    Watanabe T, Sano M, Takashima S, Kitaya T, Tokuda Y, Yoshimoto M, Kohno N, Nakagami K, Iwata H, Shimozuma K, Sonoo H, Tsuda H, Sakamoto G, Ohashi Y.
    J Clin Oncol; 2009 Mar 20; 27(9):1368-74. PubMed ID: 19204202
    [Abstract] [Full Text] [Related]

  • 14. A preliminary report of a pilot randomized trial comparing cyclophosphamide, methotrexate and 5-fluorouracil with cyclophosphamide, mitoxantrone and 5-fluorouracil in the adjuvant therapy of stage II breast cancer with four or more positive axillary nodes.
    Isacson R, Safra T, Ben-Dor CG, Uziely B, Brufman G.
    Anticancer Drugs; 1993 Apr 20; 4(2):189-92. PubMed ID: 8490197
    [Abstract] [Full Text] [Related]

  • 15. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in premonopausal patients with node-positive breast cancer: indirect comparison of dose and schedule in DBCG trials 77, 82, and 89.
    Ejlertsen B, Mouridsen HT, Jensen MB.
    Acta Oncol; 2008 Apr 20; 47(4):662-71. PubMed ID: 18465334
    [Abstract] [Full Text] [Related]

  • 16. Adjuvant doxorubicin and cyclophosphamide versus cyclophosphamide, methotrexate, and 5-fluorouracil chemotherapy in premenopausal women with axillary lymph node positive breast carcinoma.
    Bang SM, Heo DS, Lee KH, Byun JH, Chang HM, Noh DY, Choe KJ, Bang YJ, Kim SR, Kim NK.
    Cancer; 2000 Dec 15; 89(12):2521-6. PubMed ID: 11135211
    [Abstract] [Full Text] [Related]

  • 17. Second malignancies following adjuvant chemotherapy: 6-year results from a Belgian randomized study comparing cyclophosphamide, methotrexate and 5-fluorouracil (CMF) with an anthracycline-based regimen in adjuvant treatment of node-positive breast cancer patients.
    Bernard-Marty C, Mano M, Paesmans M, Accettura C, Munoz-Bermeo R, Richard T, Kleiber K, Cardoso F, Lobelle JP, Larsimont D, Piccart MJ, Di Leo A.
    Ann Oncol; 2003 May 15; 14(5):693-8. PubMed ID: 12702521
    [Abstract] [Full Text] [Related]

  • 18. Oral ondansetron in the prophylaxis of nausea and vomiting induced by cyclophosphamide, methotrexate and 5-fluorouracil (CMF) in women with breast cancer. Results of a prospective, randomized, double-blind, placebo-controlled study.
    Buser KS, Joss RA, Piquet D, Aapro MS, Cavalli F, Haefliger JM, Jungi WF, Bauer J, Obrist R, Brunner KW.
    Ann Oncol; 1993 Jun 15; 4(6):475-9. PubMed ID: 8353089
    [Abstract] [Full Text] [Related]

  • 19. Lacrimal duct stenosis and other ocular toxicity associated with adjuvant cyclophosphamide, methotrexate and 5-fluorouracil combination chemotherapy for early stage breast cancer.
    Stevens A, Spooner D.
    Clin Oncol (R Coll Radiol); 2001 Jun 15; 13(6):438-40. PubMed ID: 11824881
    [Abstract] [Full Text] [Related]

  • 20. Methylprednisolone versus metoclopramide as antiemetic treatment in patients receiving adjuvant cyclophosphamide, methotrexate, 5-fluorouracil (CMF) chemotherapy: a randomized crossover blind study.
    Gez E, Sulkes A, Ochayon L, Gera C, Nathan S, Cass Y, Rubello E, Biran S.
    J Chemother; 1989 Dec 15; 1(6):365-8. PubMed ID: 2693621
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.